Difference between revisions of "Dexrazoxane (Zinecard)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 15: Line 15:
  
 
==Also known as==
 
==Also known as==
Cardioxane, Dexrazoxane hydrochloride, or Totect.
+
Cardioxane, Cyrdanax, Dexrazoxane hydrochloride, Savene, Totect.
  
 
==References==
 
==References==

Revision as of 02:12, 6 August 2017

General information

Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.[1][2][3][4][5]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Efficacy references

  1. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62. Epub 2015 Dec 23. link to original article link to PMC article PubMed

Patient drug information

Also known as

Cardioxane, Cyrdanax, Dexrazoxane hydrochloride, Savene, Totect.

References